Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.

Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, C Tucker G, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E.

Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22.

PMID:
26695443
2.

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Hatem R, Labiod D, Château-Joubert S, de Plater L, El Botty R, Vacher S, Bonin F, Servely JL, Dieras V, Bièche I, Marangoni E.

Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29974. [Epub ahead of print]

PMID:
26686064
3.

Implication de la voie PD1/PDL1 et de la voie CTLA4/CD80 dans les tumeurs urothéliales.

Pignot G, Le Goux C, Bieche I, Vacher S, Barry de Longchamps N, Sibony M, Zerbib M.

Prog Urol. 2015 Nov;25(13):762. doi: 10.1016/j.purol.2015.08.096. French. No abstract available.

PMID:
26544291
4.

IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production.

Escobar P, Bouclier C, Serret J, Bièche I, Brigitte M, Caicedo A, Sanchez E, Vacher S, Vignais ML, Bourin P, Geneviève D, Molina F, Jorgensen C, Lazennec G.

Oncotarget. 2015 Oct 6;6(30):29034-47. doi: 10.18632/oncotarget.4732.

5.

Unraveling the Role of Huntingtin in Breast Cancer Metastasis.

Thion MS, McGuire JR, Sousa CM, Fuhrmann L, Fitamant J, Leboucher S, Vacher S, du Montcel ST, Bièche I, Bernet A, Mehlen P, Vincent-Salomon A, Humbert S.

J Natl Cancer Inst. 2015 Aug 20;107(10). pii: djv208. doi: 10.1093/jnci/djv208. Print 2015 Oct.

PMID:
26293574
6.

Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.

Chiker S, Pennaneach V, Loew D, Dingli F, Biard D, Cordelières FP, Gemble S, Vacher S, Bieche I, Hall J, Fernet M.

Cell Cycle. 2015;14(19):3066-78. doi: 10.1080/15384101.2015.1078020.

PMID:
26237679
7.

MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics.

Di Benedetto M, Toullec A, Buteau-Lozano H, Abdelkarim M, Vacher S, Velasco G, Christofari M, Pocard M, Bieche I, Perrot-Applanat M.

Br J Cancer. 2015 Sep 1;113(5):773-85. doi: 10.1038/bjc.2015.267. Epub 2015 Jul 21.

PMID:
26196186
8.

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?

Cizeron-Clairac G, Lallemand F, Vacher S, Lidereau R, Bieche I, Callens C.

BMC Cancer. 2015 Jul 5;15:499. doi: 10.1186/s12885-015-1505-5.

9.

p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.

Lodillinsky C, Infante E, Guichard A, Chaligné R, Fuhrmann L, Cyrta J, Irondelle M, Lagoutte E, Vacher S, Bonsang-Kitzis H, Glukhova M, Reyal F, Bièche I, Vincent-Salomon A, Chavrier P.

Oncogene. 2016 Jan 21;35(3):344-57. doi: 10.1038/onc.2015.87. Epub 2015 Apr 20.

PMID:
25893299
10.

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.

Rondeau S, Vacher S, De Koning L, Briaux A, Schnitzler A, Chemlali W, Callens C, Lidereau R, Bièche I.

Br J Cancer. 2015 Mar 17;112(6):1059-66. doi: 10.1038/bjc.2015.60.

PMID:
25742469
11.

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

Nunes M, Vrignaud P, Vacher S, Richon S, Lièvre A, Cacheux W, Weiswald LB, Massonnet G, Chateau-Joubert S, Nicolas A, Dib C, Zhang W, Watters J, Bergstrom D, Roman-Roman S, Bièche I, Dangles-Marie V.

Cancer Res. 2015 Apr 15;75(8):1560-6. doi: 10.1158/0008-5472.CAN-14-1590. Epub 2015 Feb 24.

PMID:
25712343
12.

Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.

de Plater L, Vincent-Salomon A, Berger F, Nicolas A, Vacher S, Gravier E, Thuleau A, Karboul N, Richardson M, Elbaz C, Marangoni E, Bièche I, Paoletti X, Roman-Roman S, Culp PA, Asselain B, Diéras V, Decaudin D.

PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014.

13.

Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.

Karam M, Bièche I, Legay C, Vacher S, Auclair C, Ricort JM.

J Cell Mol Med. 2014 Dec;18(12):2536-52. doi: 10.1111/jcmm.12322. Epub 2014 Oct 7.

14.

Tubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon.

Rocha C, Papon L, Cacheux W, Marques Sousa P, Lascano V, Tort O, Giordano T, Vacher S, Lemmers B, Mariani P, Meseure D, Medema JP, Bièche I, Hahne M, Janke C.

EMBO J. 2014 Oct 1;33(19):2247-60. doi: 10.15252/embj.201488466. Epub 2014 Sep 1. Erratum in: EMBO J. 2014 Nov 18;33(22):2735.

15.

Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.

Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E.

Clin Cancer Res. 2014 Aug 15;20(16):4314-25. doi: 10.1158/1078-0432.CCR-13-3230. Epub 2014 Jun 19.

16.

Control of MT1-MMP transport by atypical PKC during breast-cancer progression.

Rossé C, Lodillinsky C, Fuhrmann L, Nourieh M, Monteiro P, Irondelle M, Lagoutte E, Vacher S, Waharte F, Paul-Gilloteaux P, Romao M, Sengmanivong L, Linch M, van Lint J, Raposo G, Vincent-Salomon A, Bièche I, Parker PJ, Chavrier P.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):E1872-9. doi: 10.1073/pnas.1400749111. Epub 2014 Apr 21.

17.

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings.

Bieche I, Vacher S, Vallerand D, Richon S, Hatem R, De Plater L, Dahmani A, Némati F, Angevin E, Marangoni E, Roman-Roman S, Decaudin D, Dangles-Marie V.

BMC Cancer. 2014 Mar 13;14:178. doi: 10.1186/1471-2407-14-178.

18.

PIK3R1 underexpression is an independent prognostic marker in breast cancer.

Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D, Callens C, Rouleau E, Spyratos F, Lidereau R, Bièche I.

BMC Cancer. 2013 Nov 14;13:545. doi: 10.1186/1471-2407-13-545.

19.

Inhibitory signalling to the Arp2/3 complex steers cell migration.

Dang I, Gorelik R, Sousa-Blin C, Derivery E, Guérin C, Linkner J, Nemethova M, Dumortier JG, Giger FA, Chipysheva TA, Ermilova VD, Vacher S, Campanacci V, Herrada I, Planson AG, Fetics S, Henriot V, David V, Oguievetskaia K, Lakisic G, Pierre F, Steffen A, Boyreau A, Peyriéras N, Rottner K, Zinn-Justin S, Cherfils J, Bièche I, Alexandrova AY, David NB, Small JV, Faix J, Blanchoin L, Gautreau A.

Nature. 2013 Nov 14;503(7475):281-4. doi: 10.1038/nature12611. Epub 2013 Oct 16.

20.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk